Experience in fractionated stereotactic body radiation therapy boost for newly diagnosed nasopharyngeal carcinoma

Chen, Helen Hai-Wen; Tsai, Sen Tien; Wang, Mei-Shu; Wu, Yuan-Hua; Hsueh, Wei; Yang, Mingwei; Yeh, I-Chun; Lin, Jin‐Ching

doi:10.1016/j.ijrobp.2006.07.1385

Cited by 45 publications

(26 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, experience at our center, and other centers, has shown that a local boost with brachytherapy or the use of stereotactic RT after treatment a 2D planning technique can significantly improve the local control rate to >90% (3,4). However, this comes at the price of an increased risk of late toxicity.…”

Section: Introductionmentioning

confidence: 89%

Whole-Field Simultaneous Integrated-Boost Intensity-Modulated Radiotherapy for Patients With Nasopharyngeal Carcinoma

Wong

Lee

et al. 2010

International Journal of Radiation Oncology*Biology*Physics

121

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 89%

Whole-Field Simultaneous Integrated-Boost Intensity-Modulated Radiotherapy for Patients With Nasopharyngeal Carcinoma

Wong

Lee

et al. 2010

International Journal of Radiation Oncology*Biology*Physics

121

View full text Add to dashboard Cite

“…The posterior neck node regions were boosted with 9-12 MeV electron beam. Nasopharyngeal tumor and gross nodes were boosted by 3D conformal RT or a frameless stereotactic body radiation therapy (SBRT; Cyberknife) to the planned dose [17]. …”

Section: Methodsmentioning

confidence: 99%

Comparison of concurrent chemoradiotherapy versus neoadjuvant chemotherapy followed by radiation in patients with advanced nasopharyngeal carcinoma in endemic area: experience of 128 consecutive cases with 5 year follow-up

Yang

et al. 2014

BMC Cancer

Self Cite

View full text Add to dashboard Cite

BackgroundCombined radiotherapy and chemotherapy is considered the standard of care for locally advanced nasopharyngeal carcinoma (LA-NPC) in Epstein-Barr virus infection endemic area. This study compared the long-term outcomes between LA-NPC patients treated with neoadjuvant chemotherapy followed by radiotherapy (NACT) and those treated with concurrent chemoradiotherapy (CCRT).MethodsFrom 2003 to 2007, a total of 128 histopathologically proven LA-NPC patients receiving either NACT or CCRT were consecutively enrolled at the National Cheng Kung University Hospital in Taiwan. NACT consisted of 3-week cycles of mitomycin, epirubicin, and cisplatin on day 1 and fluorouracil and leucovorin on day 8 (MEPFL) or weekly alternated cisplatin on day 1 and fluorouracil and leucovorin on day 8 (P-FL). CCRT comprised 3-week cycles of cisplatin (Cis 100) or 4-week cycles of cisplatin and fluorouracil (PF4). The first failure site, disease free survival (DFS), overall survival (OS), and other prognostic factors were analyzed.ResultsThirty-eight patients (30%) received NACT. Median follow-up duration was 53 months. More patients with advanced nodal disease (N2-N3) (86.8% vs 67.8%, p =0.029) and advanced clinical stage (stage IVA-IVB) enrolled in the NACT group (55.2% vs 26.7%, p =0.002). For NACT, both MEPFL and P-FL had similar 5-year DFS and OS (52.9% vs 50%, p =0.860 and 73.5% vs 62.5%, p =0.342, respectively). For CCRT, both PF4 and Cis 100 had similar 5-year DFS and OS (62.8% vs 69.6%, p =0.49 and 72.9% vs 73.9%, p =0.72, respectively). Compared to CCRT, NACT had similar 5-year DFS and OS (51.5% vs 65.1%, p =0.28 and 71.7% vs 74.3%, p =0.91, respectively). Among patients who were recurrence-free in the first 2 years after treatment, those treated with NACT experienced poorer locoregional control compared to those treated with CCRT (Hazard ratio =2.57, 95% confidence interval: 1.02 to 6.47, p =0.046).ConclusionsFor LA-NPC, both CCRT and NACT were similarly efficacious treatment strategies in terms of long-term disease control and survival probability. Close locoregional follow-up is recommended for patients receiving NACT, because these patients are more prone to develop locoregional failure than patients receiving CCRT.

show abstract

“…The overall survival rate ranged from 50%-70% depending on the stage and combination of treatment modalities (8)(9)(10). Following the introduction of modern radiotherapy treatment modalities, including three-dimensional conformal radiotherapy (3D-CRT) and intensity-modulated radiotherapy (IMRT), and treatment regimens including both IMRT and concomitant chemoradiotherapy, treatment results can reach approximately 90% for local tumor control and nearly 80%-90% for 3-year overall survival (11)(12)(13). Radiation-related late complications have become increasingly important in NPC patients since long-term survival has become possible because late complications may affect a patient's long-term quality of life.…”

Section: Introductionmentioning

confidence: 99%

Hypothyroidism After Radiotherapy for Nasopharyngeal Cancer Patients

Wang

Chen

et al. 2010

International Journal of Radiation Oncology*Biology*Physics

Self Cite

View full text Add to dashboard Cite

Experience in fractionated stereotactic body radiation therapy boost for newly diagnosed nasopharyngeal carcinoma

Cited by 45 publications

References 45 publications

Whole-Field Simultaneous Integrated-Boost Intensity-Modulated Radiotherapy for Patients With Nasopharyngeal Carcinoma

Whole-Field Simultaneous Integrated-Boost Intensity-Modulated Radiotherapy for Patients With Nasopharyngeal Carcinoma

Comparison of concurrent chemoradiotherapy versus neoadjuvant chemotherapy followed by radiation in patients with advanced nasopharyngeal carcinoma in endemic area: experience of 128 consecutive cases with 5 year follow-up

Hypothyroidism After Radiotherapy for Nasopharyngeal Cancer Patients

Contact Info

Product

Resources

About